FDA clears Novus's hernia repair mesh
This article was originally published in Clinica
The TIGR Matrix surgical mesh developed by Novus Scientific has gained 510(k) clearance from the US FDA. The resorbable mesh can now be used to reinforce soft tissues, the Singapore company says. The matrix is knitted from two different resorbable fibres that degrade at different rates following implantation, and has a macroporous structure designed to allow tissue integration. The product will be used to treat inguinal hernia patients initially, and could be used in ventral and incisional hernia in future.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.